TB-500 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-29 and is reviewed periodically as new material appears.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
| Property | Value | Notes |
|---|---|---|
| Analytical method | LC-MS/MS | Preferred confirmatory technique |
| Appearance | White to off-white powder | Lyophilised form |
| Solubility | Freely soluble in water | Also described in saline |
| Storage temperature | Below -20 °C for powder | Short-term refrigeration for solutions |
| Regulatory status | Prohibited in sport | Listed under peptide hormones |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
== Licensing and regulation == In the European Union, in the scope of medical devices, the European Court places them in some relation to a specific medical purpose: treating a disease or illness. The Court held that regulating devices that do not explicitly manifest medical benefits as medical devices would run counter to the rationale and lead to overregulation. "The legal foundation for regulating medical devices in the EU is the MDR (Regulation (EU) 2017/745), which was adopted in 2016 and came into effect in 2021. The MDR stipulates that for non-medical devices, the 'requirement to demonstrate a clinical benefit (…) shall be understood as a requirement to demonstrate the performance of the device' (Article 61 para 9 MDR). In other words, devices must demonstrate that they function in the way claimed by manufacturers, instead of showing a therapeutic benefit. Moreover, with respect to the safety of non-medical Annex XVI devices, the MDR lays down the following: For the devices referred to in Annex XVI, the general safety requirements (…) shall be understood to mean that the device, when used under the conditions and for the purposes intended, does not present a risk at all or presents a risk that is no more than the maximum acceptable risk related to the product's use which is consistent with a high level of protection for the safety and health of persons(MDR, Annex I, Article 9). The MDR sets an absolute risk threshold for the non-medical devices listed in Annex XVI, including non-invasive brain stimulation.
In times of crisis, as in 1936–1938, such pressure has taken the form of intimidation and assassination. At present time, nonconformity regarding any important question on which the Arab Higher Committee has pronounced a policy is represented as disloyalty to the Arab nation.
=== Liver transplant === In people who develop acute liver failure or who are otherwise expected to die from liver failure, the mainstay of management is liver transplantation. Liver transplants are performed in specialist centers. The most commonly used criteria for liver transplant were developed by physicians at King's College Hospital in London. Patients are recommended for transplant if they have an arterial blood pH less than 7.3 after fluid resuscitation or if a patient has Grade III or IV encephalopathy, a prothrombin time greater than 100 seconds, and a serum creatinine greater than 300 mmol/L In a 24-hour period. Other forms of liver support have been used including partial liver transplants. These techniques have the advantage of supporting the patient while their own liver regenerates. Once liver function returns immunosuppressive drugs are commenced and they have to take immunosuppressive medication for the rest of their lives.
=== Serotonin 5-HT2A receptor antagonists === Serotonin 5-HT2A receptor antagonists such as ritanserin, ketanserin, eplivanserin, volinanserin, nelotanserin, and pimavanserin have been studied and developed to improve sleep. They do not improve sleep onset, but have been found to increase slow wave sleep (deep sleep) and reduce nighttime awakenings. Conversely, improvement in subjective sleep ratings have been more mixed. Ultimately no selective serotonin 5-HT2A receptor antagonists have been approved for treatment of insomnia. The only selective serotonin 5-HT2A receptor antagonist to be approved for any indication is pimavanserin for treatment of Parkinson's disease psychosis. Besides selective serotonin 5-HT2A receptor antagonists however, many non-selective agents used as hypnotics show serotonin 5-HT2A receptor antagonism, for instance antidepressants like trazodone, mirtazapine, and amitriptyline, antipsychotics like quetiapine and olanzapine, and antihistamines like hydroxyzine and cyproheptadine.
=== Bioanalytical methods === Bioanalytical methods are necessary to construct a concentration-time profile. Chemical techniques are employed to measure the concentration of drugs in biological matrix, most often plasma. Proper bioanalytical methods should be selective and sensitive. For example, microscale thermophoresis can be used to quantify how the biological matrix/liquid affects the affinity of a drug to its target.
Sources: en.wikipedia.org
Carvedilol, sold under the brand name Coreg among others, is a beta blocker medication, that may be prescribed for the treatment of high blood pressure (hypertension) and chronic heart failure with reduced ejection fraction (also known as HFrEF or systolic heart failure). Beta-blockers as a collective medication class are not recommended as routine first-line treatment of high blood pressure for all patients, due to evidence demonstrating less effective cardiovascular protection and a less favourable safety profile when compared to other classes of blood pressure-lowering medications. Common side effects include dizziness, tiredness, slowed heart rate, low blood pressure, nausea, and shortness of breath. Severe side effects may include bronchospasm. Safety during pregnancy or breastfeeding is unclear. Use is not recommended in those with liver problems. Carvedilol is a nonselective beta blocker and alpha-1 blocker. How it improves outcomes is not entirely clear but may involve dilation of blood vessels. Carvedilol was patented in 1978 and approved for medical use in the United States in 1995. Carvedilol is a therapeutic alternative on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 35th most commonly prescribed medication in the United States, with more than 16 million prescriptions.
Given this uncertainty, between April–May 2006 at the JINR, a FLNR–PSI team conducted experiments probing the synthesis of this isotope as a daughter in the nuclear reaction 242Pu(48Ca,3n)287Fl. (The 242Pu + 48Ca fusion reaction has a slightly larger cross-section than the 238U + 48Ca reaction, so that the best way to produce copernicium for chemical experimentation is as an overshoot product as the daughter of flerovium.) In this experiment, two atoms of copernicium-283 were unambiguously identified and the adsorption properties were interpreted to show that copernicium is a more volatile homologue of mercury, due to formation of a weak metal-metal bond with gold. This agrees with general indications from some relativistic calculations that copernicium is "more or less" homologous to mercury. However, it was pointed out in 2019 that this result may simply be due to strong dispersion interactions. In April 2007, this experiment was repeated and a further three atoms of copernicium-283 were positively identified. The adsorption property was confirmed and indicated that copernicium has adsorption properties in agreement with being the heaviest member of group 12. These experiments also allowed the first experimental estimation of copernicium's boiling point: 84+112−108 °C, so that it may be a gas at standard conditions. Because the lighter group 12 elements often occur as chalcogenide ores, experiments were conducted in 2015 to deposit copernicium atoms on a selenium surface to form copernicium selenide, CnSe.
In March 2022, the first "Fridays and Go", a takeaway and quick service version of TGI Fridays, launched in Dundee, Scotland. Despite initial plans to open up to thirty other branches, it remained the sole example until it closed in October 2024 following the sale of the bankrupt UK franchise. In December 2023, SouthRock Capital, the operator of all of the TGI Fridays locations in Brazil, declared bankruptcy, continuing to operate most TGI Fridays locations normally while closing a few underperforming ones, while restructuring through the bankruptcy procedure. SouthRock Capital later declared Chapter 15 bankruptcy in June 2024. On January 4, 2024, TGI Fridays abruptly closed 36 underperforming restaurants and sold eight more to former CEO Ray Blanchette. Most employees were offered transfer to other locations. In April 2024, TGI Fridays entered an agreement to be acquired by Hostmore LLC, the owner of TGI Friday's restaurants in the UK, and for the combined company to go public on the London Stock Exchange. In May 2024 in the US, TGI Friday's entered a licensing agreement with Kraft Heinz to sell TGI Fridays-branded appetizers in supermarkets.
== Biology / Functions == Efficient presentation of antigenic peptides by MHC class I molecules provides the key signal for adaptive immune responses by cytotoxic (CD8+) T lymphocytes. In the "endogenous" antigen presentation pathway, proteins synthesized by cells undergo cytosolic degradation and some of their peptide fragments are transported to the ER, where suitable-length peptides are loaded onto MHC class I molecules. In the ER, ERAP1 shortens longer peptides to the optimal length for stable binding onto MHC class I molecules (Figure 1). ERAP1, like other APP components, is induced by interferon gamma, a cytokine inducing antigen presentation. ERAP1 preferentially trims N-extended substrates of 9-16 residues to optimally sized 8-10 residue peptides. This "molecular ruler" mechanism is unique to ERAP1. ERAP1 also functions in the presentation of extracellular antigens in the cross-presentation pathway. ERAP1 "trimming" modulates the peptide repertoire presented by MHC class I molecules and thereby shapes the adaptive immune response. In murine models, ERAAP (the murine homologue of human ERAP1) deficiency results in a strong alteration and increased immunogenicity of the peptide repertoire presented by MHC-I. Murine models with genetic deficiency for ERAAP have been instrumental for understanding the role of peptide trimming in the ER. Besides peptide trimming in the ER, ERAP1 has been proposed to perform additional functions depending on its location.
R-NH2 + DBNPA → R-NH-C(Br)(NO2)NH2 In basic environments, DBNPA undergoes nucleophilic substitution by hydroxide ions, which initiates hydrolysis. This reaction reduces the environmental persistence of DBNPA by breaking it down into smaller degradation products.
Sources: en.wikipedia.org
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.
Dry lyophilised powder is normally kept frozen and protected from moisture and light. Dissolved material is handled cold and used promptly to limit degradation.
It is not licensed as a medicine in major markets and is distributed as a research chemical. Sports organisations prohibit its use, and some countries restrict import and supply.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.